Composition and Method for Treating Neurological Disease (2018)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 15/898,148, filed Feb 15, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,213,394 | Composition and Method for Treating Neurological Disease In force · High confidence UsedRemaining | Adamas Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,500,171 | Composition and Method for Treating Neurological Disease In force · High confidence | Adamas Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,500,172 | Composition and Method for Treating Neurological Disease In force · High confidence | Adamas Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,890,261 | Composition and Method for Treating Neurological Disease In force · Low confidence | Adamas Pharmaceuticals, Inc. | In force | Low confidence | ||
| Application 16/670,807 | Composition and Method for Treating Neurological Disease Abandoned Abandoned Apr 9, 2021 | Adamas Pharmaceuticals, Inc. | Abandoned | Abandoned Apr 9, 2021 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Adamas Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.